Forte Research Systems has Created the Allegro® ePayments System for Research Sites and their Patients.
June 26, 2012 – Eliminating time and costs associated with issuing checks or tracking cash payments to patients who participate in clinical research studies is now a reality due to a partnership between Forte Research Systems®, Inc. and one of the largest commercial banks in the United States. With seamlessly integrated systems, the bank and the clinical research software provider have come together to offer unprecedented efficiencies and ease of use to research sites that reimburse their patient volunteers for their contribution to scientific discovery through the new Allegro®ePayments system.
“Our customers were struggling with the fact that they were losing time and money on the patient reimbursement process. For those who were still cutting checks, it was costing them about $50 to issue a $40 check,” said Srini Kalluri, CEO and Chief Customer Officer at Forte Research Systems. “We were in a position to improve this process and we found the right partner to help us make one-click patient reimbursement a reality for our customers.”
Leveraging the bank’s systems for electronic funds transfer and debit card issuance, the Allegro ePayments system is a significant improvement over other card programs used by some research sites. The new technology eliminates the need to stockpile and track inventories of preloaded cards in the physician’s office or to log in to multiple computer systems in order to transfer funds.
Cardholders receive a personalized, prepaid debit card in the mail soon after their initial session. Payments are loaded directly to the patient's card, eliminating wait time for a check in the mail. Patients can then use their cards to make purchases, withdrawal cash and track their balance over the phone or online.
The system is a further improvement on existing technologies because patient payments are automatically reconciled within the financial management functionality of their clinical trial management system (CTMS). With Allegro ePayments, the research site is always in control of clinical trial financials and can respond to subject visit events in real time.
Improved Patient Reimbursement Process for Research Sites
Improved Patient Experience
Ability to track card balance by phone, website, or mobile application.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.